Thursday, December 7, 2023
No Result
View All Result
No Result
View All Result

Bristol-Myers Squibb Company (BMY) Stock Forecast & Price Prediction

Estimation of the future price movement of Bristol-Myers Squibb Company stock, based on various factors such as historical price trends, market trends, company performance, and economic conditions.

Price target


Current $49.88

Concensus $72.10

Low $60.00

Median $72.50

High $85.00

Based on analysts projections #BMY is expected to experience a positive growth trajectory over the next year.

The current average BMY price target, as estimated by these analysts, is $72.10.

The predictions for the future BMY stock price range from a low of $60.00 to a high of $85.00, highlighting the variability of market expectations for BMY.

It is important to note that market fluctuations and unforeseen events can have an impact on these projections, so investors should always exercise caution and conduct thorough research before making any investment decisions.

BMY stock forecasts by analyst

Analyst / firm Date Rating Price target Price when posted
Evan Seigerman
BMO Capital 		November 27, 2023 Buy 60.00 49.76
David Risinger
Leerink Partners 		October 12, 2023 Buy 66.00 56.25
Louise Chen
Cantor Fitzgerald 		September 6, 2023 Buy 75.00 59.67
Mohit Bansal
Wells Fargo 		May 18, 2022 Buy 70.00 78.22
BMO Capital May 2, 2022 Buy 92.00 75.66
Barclays May 2, 2022 Buy 68.00 75.27
Seamus Fernandez
Guggenheim 		May 2, 2022 Buy 80.00 75.27
Evan Seigerman
BMO Capital 		May 2, 2022 Buy 87.00 75.08
Terence Flynn
Morgan Stanley 		April 11, 2022 Buy 64.00 76.50
Evan Seigerman
BMO Capital 		April 4, 2022 Buy 81.00 73.79
Matthew Harrison
Morgan Stanley 		March 28, 2022 Buy 66.00 73.11
Evan David Seigerman
BMO Capital 		March 17, 2022 Buy 74.00 70.52
Carter Gould
Barclays 		October 28, 2021 Buy 66.00 56.22
Andrew Baum
Citigroup 		October 25, 2021 Buy 75.00 56.89
Seamus Fernandez
Guggenheim 		September 20, 2021 Buy 82.00 59.05
Justin Smith
Societe Generale 		September 7, 2021 Buy 85.00 63.63
Geoff Meacham
Bank of America Securities 		July 27, 2021 Buy 78.00 65.88

Bristol-Myers Squibb Company (BMY) Fundamentals Checker

Financial metrics are used to evaluate financial stability which helps analysts determine if Bristol-Myers Squibb Company is undervalued compared to its fair value. A company's financial health can strongly influence the stock forecast.

Strong Buy

Financial Scores

Updated on: 07/12/2023

Altman Z-Score: 2.3

Piotroski Score: 7.0

ESG Score

Updated on: 07/12/2023

Environmental: 74.9

Social: 64.7

Governance: 71.1

Financial Health

Updated on: 07/12/2023

DCF: Strong Buy

ROE: Neutral

ROA: Neutral

Debt to equity ratio: Strong Buy

Price to earnings ratio: Strong Buy

Price to book ratio: Strong Buy

BMY Discounted Cash Flow

Updated on: 07/12/2023

$56.071
Discounted Cash Flow Value

$49.880
Current Price

BMY Revenues by Segment

Updated on: 07/12/2023

Abecma
$3,880,000.00
Abraxane
$8,110,000.00
Breyanzi
$1,820,000.00
Eliquis
$117,890,000.00
Empliciti
$2,960,000.00
Inrebic
$850,000.00
Mature Products And All Other
$17,490,000.00
Onureg
$1,240,000.00
Opdivo
$82,490,000.00
Opdualag
$2,520,000.00
Orencia
$34,640,000.00
Pomalyst/Imnovid
$34,970,000.00
Reblozyl
$7,170,000.00
Revlimid
$99,780,000.00
Sprycel
$21,650,000.00
Yervoy
$21,310,000.00
Zeposia
$2,500,000.00

Revenue from Contract with Customer, Excluding Assessed Tax

BMY Revenues by Region

Updated on: 07/12/2023

European Union
$134,970,000.00
Other Region
$8,340,000.00
UNITED STATES
$318,280,000.00

BMY Notes Due

Updated on: 07/12/2023

CIKExchangeTitle
0000014272 NYSE 1.750% Notes due 2035
0000014272 NYSE 1.000% Notes due 2025

Bristol-Myers Squibb Company (BMY) Social Sentiments

Monitoring bullish and bearish sentiments towards Bristol-Myers Squibb Company on Twitter and Stocktwits could help to forecast an upward or downward trend in Bristol-Myers Squibb Company stock price.

Positive Stock Forecast for Bristol-Myers Squibb Company: Robust Growth, Acquisitions, and Partnerships in the Pharmaceutical Industry

Bristol-Myers Squibb Company (BMY) is a leading pharmaceutical company operating in the Drug Manufacturers - General sector. With a robust product portfolio and dedicated research and development, BMY has emerged as one of the strongest players in the industry. Founded in 1858, BMY has come a long way from its roots as a drug importer to its present-day status as... Read more

Stock Prediction: Bristol-Myers Squibb Company's Positive Outlook in the Drug Manufacturers - General Sector

The Drug Manufacturers - General sector of the stock market is an important one as it includes companies that are involved in the research, development, and manufacture of pharmaceutical products. These companies have a huge impact on the health industry and on people’s lives around the world. One company that stands out in this sector is Bristol-Myers Squibb Company. Bristol-Myers...
One reason for this positive outlook may be due to the fact that Bristol-Myers recently acquired Celgene Corporation which has bolstered their product portfolio and pipeline. This acquisition provides them with several new drugs in development and expands their reach into oncology treatment options. Additionally, their focus on developing treatments for chronic conditions such as cardiovascular disease also bodes well considering its increasing prevalence among aging populations globally.

Another factor that may contribute to BMY's positive potential is its strong financial position with solid revenue growth over the past two years along with relatively low debt levels compared to peers.

Overall conclusion:

While nothing is guaranteed when it comes to predicting stock prices, Bristol-Myers Squibb Company (BMY) has shown promise as a solid investment opportunity in the Drug Manufacturers - General sector. With a strong product portfolio, acquisition of Celgene Corporation, and expansion into new markets, BMY is well-positioned for growth.">Read more
No Result
View All Result

© 2023 Best Stocks